SAN FRANCISCO (MarketWatch) — Gilead Sciences Inc., AT&T Inc. and Amgen Inc. were among the stocks actively trading Tuesday evening, with shares of Gilead climbing after handily beating Wall Street's quarterly earnings and revenue expectations and reporting a sales surge for its new hepatitis C treatment.
Bloomberg News 
Enlarge Image Gilead Sciences (GILD) reported late Tuesday that non-GAAP first-quarter net income, which excludes acquisition expenses and other one-off items, was $1.48 a share and said revenue reached $5 billion. The research-based biopharmaceutical company was expected to post quarterly earnings of 92 cents a share on revenue of $3.96 billion, according to FactSet consensus estimates.
Shares of Gilead climbed 2.3% Tuesday evening after a halt in after-hours trading. The company also said sales of its new treatment for hepatitis C soared in the first quarter, helping the biopharmaceutical company's bottom-line to triple.
AT&T (T) saw an adjusted profit of 71 cents a share and said revenue grew 3.6% to $32.5 billion in the first quarter. That compared with analyst expectations for earnings of 70 cents a share and revenue of $32.4 billion. Shares of AT&T fell 1.9% in after-hours dealings.
The telecommunication giant also raised its revenue outlook for the year, projecting growth of 4% or more, versus its previous call for a 2% to 3% increase.
Earnings Wall Discuss key earnings announcements before and after results come in. Learn more
No comments:
Post a Comment